$HRGN
Harvard Apparatus Regenerative Technology, Inc.

2021 Q4 Form 10-K Financial Statement

#000155837022004945 Filed on March 31, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.351M $7.044M $787.0K
YoY Change 579.92% 116.34% -6.64%
% of Gross Profit
Research & Development $550.0K $1.592M
YoY Change -23.05%
% of Gross Profit
Depreciation & Amortization $20.00K $107.0K $45.00K
YoY Change -55.56% -41.85% -8.16%
% of Gross Profit
Operating Expenses $5.901M $8.636M $1.110M
YoY Change 431.62% 62.18% -33.49%
Operating Profit -$8.636M
YoY Change 62.18%
Interest Expense $2.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net $28.00K $658.0K $84.00K
YoY Change -66.67% 43.04% 20.0%
Pretax Income -$5.873M -$7.978M -$1.024M
YoY Change 473.54% 63.99% -35.96%
Income Tax
% Of Pretax Income
Net Earnings -$5.873M -$7.978M -$1.024M
YoY Change 473.54% 63.99% -35.96%
Net Earnings / Revenue
Basic Earnings Per Share -$0.79
Diluted Earnings Per Share -$514.9K -$0.79 -$109.0K
COMMON SHARES
Basic Shares Outstanding 10.69M 10.06M
Diluted Shares Outstanding 10.06M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.242M $1.242M $1.026M
YoY Change 21.05% 21.05% 12.38%
Cash & Equivalents $1.292M $1.076M
Short-Term Investments
Other Short-Term Assets $12.00K $345.0K $24.00K
YoY Change -50.0% -39.9% -95.14%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $77.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.587M $1.587M $1.677M
YoY Change -5.37% -5.37% 19.19%
LONG-TERM ASSETS
Property, Plant & Equipment $110.0K $279.0K $217.0K
YoY Change -49.31% -30.08% -62.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $279.0K $279.0K $399.0K
YoY Change -30.08% -30.08% -31.79%
TOTAL ASSETS
Total Short-Term Assets $1.587M $1.587M $1.677M
Total Long-Term Assets $279.0K $279.0K $399.0K
Total Assets $1.866M $1.866M $2.076M
YoY Change -10.12% -10.12% 4.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $676.0K $676.0K $31.00K
YoY Change 2080.65% 2080.65% -87.14%
Accrued Expenses $4.158M $4.158M $424.0K
YoY Change 880.66% 942.11% -21.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $284.0K
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $4.836M $4.836M $756.0K
YoY Change 539.68% 539.68% -7.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $120.0K
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $59.00K $59.00K $75.00K
YoY Change -21.33% -21.33% -15.73%
Total Long-Term Liabilities $59.00K $59.00K $195.0K
YoY Change -69.74% -69.74% 119.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.836M $4.836M $756.0K
Total Long-Term Liabilities $59.00K $59.00K $195.0K
Total Liabilities $4.895M $4.895M $951.0K
YoY Change 414.72% 414.72% 5.32%
SHAREHOLDERS EQUITY
Retained Earnings -$76.94M -$68.96M
YoY Change 11.57%
Common Stock $108.0K $94.00K
YoY Change 14.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.029M -$3.029M $1.125M
YoY Change
Total Liabilities & Shareholders Equity $1.866M $1.866M $2.076M
YoY Change -10.12% -10.12% 4.22%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$5.873M -$7.978M -$1.024M
YoY Change 473.54% 63.99% -35.96%
Depreciation, Depletion And Amortization $20.00K $107.0K $45.00K
YoY Change -55.56% -41.85% -8.16%
Cash From Operating Activities -$1.001M -$2.628M -$1.022M
YoY Change -2.05% -34.97% -29.18%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 248.0K 2.844M 0.000
YoY Change -31.65% -100.0%
NET CHANGE
Cash From Operating Activities -1.001M -2.628M -1.022M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 248.0K 2.844M 0.000
Net Change In Cash -753.0K 216.0K -1.022M
YoY Change -26.32% 91.15% 452.43%
FREE CASH FLOW
Cash From Operating Activities -$1.001M -$2.628M -$1.022M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$1.001M -$2.628M -$1.022M
YoY Change -2.05% -35.08% -28.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 bstg Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
-77000
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10062432
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8793545
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001563665
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei No Trading Symbol Flag
NoTradingSymbolFlag
true
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10062432
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8793545
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10760871
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9388407
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-35853
CY2021 dei Entity Registrant Name
EntityRegistrantName
BIOSTAGE, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5210462
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
84 October Hill Road, Suite 11
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Holliston
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01746
CY2021 dei City Area Code
CityAreaCode
774
CY2021 dei Local Phone Number
LocalPhoneNumber
233-7300
CY2021 dei Security12b Title
Security12bTitle
None
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
8058400
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10760871
CY2021 dei Auditor Firm
AuditorFirmId
2388
CY2021 dei Auditor Name
AuditorName
Wei, Wei & Co., LLP
CY2021 dei Auditor Location
AuditorLocation
Flushing, New York
dei Auditor Name
AuditorName
RSM US LLP
dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021Q4 us-gaap Cash
Cash
1242000
CY2020Q4 us-gaap Cash
Cash
1026000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2021Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
0
CY2020Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
77000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
295000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
524000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1587000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1677000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
217000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
169000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
182000
CY2021Q4 us-gaap Assets
Assets
1866000
CY2020Q4 us-gaap Assets
Assets
2076000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
676000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
31000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
798000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
317000
CY2021Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
3250000
CY2020Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
284000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2000
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
17000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
110000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
107000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4836000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
756000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
120000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
59000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
75000
CY2021Q4 us-gaap Liabilities
Liabilities
4895000
CY2020Q4 us-gaap Liabilities
Liabilities
951000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10760871
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9388407
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
108000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
94000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
73801000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69991000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76938000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68960000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3029000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-16000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
70000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
658000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
460000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-7978000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-4865000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1125000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1866000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2076000
CY2021 us-gaap Revenues
Revenues
0
CY2020 us-gaap Revenues
Revenues
0
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1592000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2069000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7044000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3256000
CY2021 us-gaap Operating Expenses
OperatingExpenses
8636000
CY2020 us-gaap Operating Expenses
OperatingExpenses
5325000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-8636000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-5325000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
408000
CY2021 bstg Grant Income
GrantIncome
165000
CY2020 bstg Grant Income
GrantIncome
447000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-15000
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10062432
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8793545
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1089000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-4865000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1144000
CY2020 bstg Common Stock With Held For Taxes
CommonStockWithHeldForTaxes
-42000
CY2020 bstg Issuance Of Common Stock And Warrants To Purchase Common Stock Value Net Of Offering Costs
IssuanceOfCommonStockAndWarrantsToPurchaseCommonStockValueNetOfOfferingCosts
1058000
CY2020 bstg Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
2741000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1125000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-7978000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
980000
CY2021 bstg Issuance Of Common Stock And Warrants To Purchase Common Stock Value Net Of Offering Costs
IssuanceOfCommonStockAndWarrantsToPurchaseCommonStockValueNetOfOfferingCosts
2844000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3029000
CY2021 us-gaap Profit Loss
ProfitLoss
-7978000
CY2020 us-gaap Profit Loss
ProfitLoss
-4865000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
408000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
980000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1144000
CY2021 us-gaap Depreciation
Depreciation
107000
CY2020 us-gaap Depreciation
Depreciation
184000
CY2021 bstg Fair Value Adjustment Of Warrants Gross
FairValueAdjustmentOfWarrantsGross
-15000
CY2020 bstg Fair Value Adjustment Of Warrants Gross
FairValueAdjustmentOfWarrantsGross
-16000
CY2020 bstg Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
77000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-229000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
80000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
645000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-210000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
485000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-121000
CY2021 bstg Increase Decrease In Accrual For Contingency Matter
IncreaseDecreaseInAccrualForContingencyMatter
3250000
CY2020 bstg Increase Decrease In Accrual For Contingency Matter
IncreaseDecreaseInAccrualForContingencyMatter
0
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2628000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4041000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2844000
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1058000
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
CY2020 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2741000
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
404000
CY2021 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2020 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
42000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2844000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4161000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
216000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
113000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1076000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
963000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1292000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1076000
CY2021 bstg Issuance Of Vested Stock In Non Cash Investing Or Financing Activity
IssuanceOfVestedStockInNonCashInvestingOrFinancingActivity
0
CY2020 bstg Issuance Of Vested Stock In Non Cash Investing Or Financing Activity
IssuanceOfVestedStockInNonCashInvestingOrFinancingActivity
42000
CY2021 bstg Increase Of Right Of Use Asset And Liability Due To Lease Extension
IncreaseOfRightOfUseAssetAndLiabilityDueToLeaseExtension
94000
CY2020 bstg Increase Of Right Of Use Asset And Liability Due To Lease Extension
IncreaseOfRightOfUseAssetAndLiabilityDueToLeaseExtension
94000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76900000
CY2021Q4 us-gaap Cash
Cash
1200000
CY2021 bstg Number Of Wholly Owned Subsidiaries
NumberOfWhollyOwnedSubsidiaries
3
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The process of preparing consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, share-based compensation, valuation of warrant liability, accrued expenses and the valuation allowance for deferred income taxes. Actual results could differ from those estimates.</p>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Cash
Cash
1242000
CY2020Q4 us-gaap Cash
Cash
1026000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1292000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1076000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
50000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2614000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2614000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2504000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2397000
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q4 bstg Prepaid Deposits
PrepaidDeposits
225000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
58000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
403000
CY2020Q4 bstg Prepaid Sponsored Research
PrepaidSponsoredResearch
97000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
12000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial investments that potentially subject the Company to credit risk consist of cash. The Company has all cash at accredited financial institutions. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. The Company does not believe that it is subject to unual credit risk beyond the normal credit risk associated with commercial banking relationships.</p>
CY2021Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
24000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
295000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
524000
CY2018Q1 bstg Maximum Research And Development Expenses Reimbursement
MaximumResearchAndDevelopmentExpensesReimbursement
200000
CY2021Q4 us-gaap Grants Receivable
GrantsReceivable
1800000
CY2021 bstg Grants Receivable Recognized
GrantsReceivableRecognized
1500000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
50000
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
2000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
50000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
17000
CY2020 bstg Fair Value Transfers Between Level Hierarchies
FairValueTransfersBetweenLevelHierarchies
0
CY2021 bstg Fair Value Transfers Between Level Hierarchies
FairValueTransfersBetweenLevelHierarchies
0
CY2021Q4 bstg Accrued Advisory Costs Current
AccruedAdvisoryCostsCurrent
151000
CY2020Q4 bstg Accrued Advisory Costs Current
AccruedAdvisoryCostsCurrent
75000
CY2021Q4 bstg Accrued Audit Services Current
AccruedAuditServicesCurrent
59000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
217000
CY2021 us-gaap Depreciation
Depreciation
107000
CY2020 us-gaap Depreciation
Depreciation
184000
CY2021Q4 bstg Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
577000
CY2020Q4 bstg Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
17000
CY2020Q4 bstg Accrued Audit Services Current
AccruedAuditServicesCurrent
161000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
39000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
25000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
798000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
317000
CY2017Q4 bstg Warrants To Be Remeasured Number
WarrantsToBeRemeasuredNumber
1044396
CY2017Q4 bstg Warrants To Be Modified Number
WarrantsToBeModifiedNumber
952184
CY2021Q4 bstg Warrants To Be Remeasured Number
WarrantsToBeRemeasuredNumber
92212
CY2022Q1 bstg Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Expired
SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExpired
92212
CY2021 bstg Fair Value Assumption Risk Free Interest Rate
FairValueAssumptionRiskFreeInterestRate
0.0005
CY2020 bstg Fair Value Assumption Risk Free Interest Rate
FairValueAssumptionRiskFreeInterestRate
0.0012
CY2021 bstg Fair Value Assumptions Expected Volatility Rates
FairValueAssumptionsExpectedVolatilityRates
174.54
CY2020 bstg Fair Value Assumptions Expected Volatility Rates
FairValueAssumptionsExpectedVolatilityRates
137.89
CY2021 bstg Fair Value Assumptions Expected Terms
FairValueAssumptionsExpectedTerms
P0Y1M6D
CY2020 bstg Fair Value Assumptions Expected Terms
FairValueAssumptionsExpectedTerms
P1Y1M6D
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.00
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.00
CY2021Q4 us-gaap Share Price
SharePrice
2.30
CY2020Q4 us-gaap Share Price
SharePrice
1.25
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
33000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-16000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
17000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-15000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2000
CY2017Q2 bstg Number Of Synthetic Trachea Scaffold Product
NumberOfSyntheticTracheaScaffoldProduct
1
CY2017Q2 bstg Number Of Bioreactors
NumberOfBioreactors
2
CY2021 bstg Increase Decrease In Accrual For Contingency Matter
IncreaseDecreaseInAccrualForContingencyMatter
3300000
CY2021Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2021 us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
false
CY2021 bstg Lessee Operating Lease Notice For Termination
LesseeOperatingLeaseNoticeForTermination
P180D
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
169000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
182000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
110000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
107000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
59000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
75000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
169000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
182000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
121000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
121000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y11M1D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0914
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1016
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
121000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
121000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
121000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
55000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
183000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
169000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1078000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.063
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.063
CY2021 bstg Effective Income Tax Rate Reconciliation Nondeductible Expense Change In Fair Value Of Warrants And Share Based Payment Arrangement Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantsAndShareBasedPaymentArrangementPercent
0.010
CY2020 bstg Effective Income Tax Rate Reconciliation Nondeductible Expense Change In Fair Value Of Warrants And Share Based Payment Arrangement Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantsAndShareBasedPaymentArrangementPercent
0.026
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.021
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.007
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.002
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.082
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.260
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.210
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16611000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15217000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1470000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1873000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1284000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
888000
CY2021Q4 bstg Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
46000
CY2020Q4 bstg Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
50000
CY2021Q4 bstg Deferred Tax Assets Excess Book Over Tax Depreciation
DeferredTaxAssetsExcessBookOverTaxDepreciation
21000
CY2020Q4 bstg Deferred Tax Assets Excess Book Over Tax Depreciation
DeferredTaxAssetsExcessBookOverTaxDepreciation
34000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
20320000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
18252000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20274000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18200000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
46000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
52000
CY2021Q4 bstg Deferred Tax Liability Operating Lease Assets
DeferredTaxLiabilityOperatingLeaseAssets
46000
CY2020Q4 bstg Deferred Tax Liability Operating Lease Assets
DeferredTaxLiabilityOperatingLeaseAssets
52000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
46000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
52000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2100000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1000000.0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
26300000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 bstg Tax Free Treatment Period For Separation And Distribution
TaxFreeTreatmentPeriodForSeparationAndDistribution
P2Y
CY2021 bstg Tax Free Treatment Period For Separation And Distribution
TaxFreeTreatmentPeriodForSeparationAndDistribution
P2Y
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2122
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.08
CY2021Q4 bstg Market Value Of Common Stock
MarketValueOfCommonStock
2.58
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
39000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
62000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
44405107
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0082
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0088
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0700
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2M
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
3.70
CY2020Q4 bstg Market Value Of Common Stock
MarketValueOfCommonStock
3.11
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.84
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1893201
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.44
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
686232
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.08
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
78014
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
35.20
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2501419
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.35
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.84
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
70000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-7978000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-4865000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10062432
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8793545
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4834022
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3492921

Files In Submission

Name View Source Status
0001558370-22-004945-index-headers.html Edgar Link pending
0001558370-22-004945-index.html Edgar Link pending
0001558370-22-004945.txt Edgar Link pending
0001558370-22-004945-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20211231.xsd Edgar Link pending
tmb-20211231x10k.htm Edgar Link pending
tmb-20211231x10k001.jpg Edgar Link pending
tmb-20211231x10k002.jpg Edgar Link pending
tmb-20211231x10k003.jpg Edgar Link pending
tmb-20211231x10k_htm.xml Edgar Link completed
tmb-20211231xex21d1.htm Edgar Link pending
tmb-20211231xex23d1.htm Edgar Link pending
tmb-20211231xex23d2.htm Edgar Link pending
tmb-20211231xex31d1.htm Edgar Link pending
tmb-20211231xex31d2.htm Edgar Link pending
tmb-20211231xex32d1.htm Edgar Link pending
tmb-20211231xex32d2.htm Edgar Link pending
tmb-20211231_cal.xml Edgar Link unprocessable
tmb-20211231_def.xml Edgar Link unprocessable
tmb-20211231_lab.xml Edgar Link unprocessable
tmb-20211231_pre.xml Edgar Link unprocessable